What top creators are saying about SPDR S&P Biotech ETF(XBI)
An exchange-traded fund that tracks the biotechnology sector.
5 AI-extracted insights from 5 sources — podcasts, YouTube channels, and X/Twitter accounts.
Creator sentiment — last 30 days
Not enough scored insights about SPDR S&P Biotech ETF in the last 30 days yet.
Top creators covering SPDR S&P Biotech ETF (XBI)
The 5 sources with the most insights about SPDR S&P Biotech ETF on Kazuha.
Latest insights about SPDR S&P Biotech ETF (XBI)
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Sunday, November 30, 2025
Emerging as a major beneficiary of applied AI, which is accelerating drug discovery and collapsing medicine costs. The ETF is trending higher and outperforming the Nasdaq 100.
Wednesday, November 26, 2025
Suggested as a potential investment to gain exposure to the biotechnology sector, which is a key focus of the U.S. government's 'Genesis Mission' AI initiative, a massive potential catalyst for the sector.
Tuesday, November 25, 2025
The ETF is described as making a 'bearish to bullish reversal' with 'a lot of space to the upside,' driven by increased M&A activity and more attractive valuations in the biotech space.
Friday, November 14, 2025
The biotech index (XBI) is starting to climb back above the $100 mark, and its recovery suggests that institutional investors may be regaining confidence, which could signal a broader turnaround.
Friday, June 27, 2025
The ETF's chart is used as evidence that the biotech sector has been 'dead' for 15 years, making broad, passive investment in the sector a poor strategy.
Sunday, November 30, 2025
Emerging as a major beneficiary of applied AI, which is accelerating drug discovery and collapsing medicine costs. The ETF is trending higher and outperforming the Nasdaq 100.
Wednesday, November 26, 2025
Suggested as a potential investment to gain exposure to the biotechnology sector, which is a key focus of the U.S. government's 'Genesis Mission' AI initiative, a massive potential catalyst for the sector.
Tuesday, November 25, 2025
The ETF is described as making a 'bearish to bullish reversal' with 'a lot of space to the upside,' driven by increased M&A activity and more attractive valuations in the biotech space.
Friday, November 14, 2025
The biotech index (XBI) is starting to climb back above the $100 mark, and its recovery suggests that institutional investors may be regaining confidence, which could signal a broader turnaround.
Friday, June 27, 2025
The ETF's chart is used as evidence that the biotech sector has been 'dead' for 15 years, making broad, passive investment in the sector a poor strategy.
Discussed alongside SPDR S&P Biotech ETF (XBI)
Other assets that creators frequently mention in the same content as SPDR S&P Biotech ETF.
Frequently asked
Which podcasters and creators cover SPDR S&P Biotech ETF (XBI) the most?
The most active sources covering SPDR S&P Biotech ETF (XBI) on Kazuha are @realmartinshkreli, RiskReversal Media, @jordivisserlabs, PHD Ventures, Andreessen Horowitz. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
How many insights about SPDR S&P Biotech ETF (XBI) are on Kazuha?
Kazuha has indexed 5 AI-extracted insights about SPDR S&P Biotech ETF (XBI) from 5 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
What other assets do creators discuss alongside SPDR S&P Biotech ETF (XBI)?
Creators covering SPDR S&P Biotech ETF (XBI) most frequently also discuss NVDA, GOOGL, BTC, SAVA, IONQ. See the "Discussed alongside" section above for full asset pages.